April 21, 2025
Focus Biomolecules will be exhibiting at the annual meeting of American Association for Cancer Research in Chicago, April 27 – 30. Stop by our booth (#1004) […]
March 20, 2025
FOCUS on drug failures. Denali Therapeutics‘ experimental drug for Amyotrophic Lateral Sclerosis (ALS) has taken another setback as the drug generated disappointing results in a phase […]
March 6, 2025
Focus on Drug Discovery. Lilly will acquire Scorpion Therapeutics’ PI3Kalpha inhibitor program which includes STX-478, a potentially best-in-class mutant-selective PI3Kα inhibitor currently being evaluated in a […]
February 26, 2025
FOCUS on Bioactive Natural Products. In a February Nature Communications paper, Wang and coworkers showed that a sesquiterpenoid found abundantly in ginger, known as furanodienone, alleviated […]
February 19, 2025
FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza™ (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) […]
February 14, 2025
FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics‘ Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas […]
February 3, 2025
Focus on drug discovery failure. Development of Risvodetinib for Parkinson’s disease was halted following disappointing Phase II results. The drug, which is a potent, brain-penetrant c-Abl […]
February 3, 2025
Focus on New Drug Approvals. The FDA approved Vertex Pharmaceutical’s Suzetrigine (VX-548) for the treatment of moderate to severe acute pain in adults. Suzetrigine is a […]
